Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density (SV2A PET Project)
The Problem Although researchers have established biomarkers to diagnose Alzheimer’s disease, no biomarker can track cognitive decline as...Biomarkers Consortium – Vol-PACT Phase II: Advanced metrics and modeling with Volumetric CT for Precision Analysis of Clinical Trial results
The Problem The cancer research field lacks well-tested biomarkers to measure disease progression and to predict how patients respond to tr...Biomarkers Consortium – Treatments Against RA and Effect on FDG PET-CT (TARGET Biomarker Study)
The Problem Rheumatoid arthritis (RA) is currently difficult to treat and people with RA are at increased risk for developing cardiovascula...Biomarkers Consortium – Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)
The Problem The earliest stages of FTD are hard to detect until the disease has progressed and damage is more permanent. Experts believe th...Biomarkers Consortium – Measurable residual disease in acute myeloid leukemia (MRD in AML)
The Problem Detection of measurable residual disease (MRD) is a strong predictor of relapse in acute and chronic leukemia, but its integrat...Biomarkers Consortium – ctDNA Quality Control Materials Project
The Problem Tumor DNA circulating in bodily fluids offers researchers a valuable tool to study, and thus to treat, cancer. Yet the wide var...Biomarkers Consortium – CSC Scientific Symposium
The Problem cancer research is a large and diverse field, making it difficult to coordinate efforts across its many subfields, which are fo...Biomarkers Consortium – Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers
The Problem When conducting clinical trials of any drugs that could cause acute kidney injury, Researchers need biomarkers that can detect ...Diseases
Learn more about the diseases we fight
Partner With Us
Work with the FNIH to accelerate medical breakthroughs for patients